Abstract
Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.
Keywords: Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.
Current Vascular Pharmacology
Title:Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update
Volume: 16 Issue: 2
Author(s): Yi-dong Wang, Zhen-jie Liu, Jun Ren and Mei-Xiang Xiang*
Affiliation:
- Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Cardiovascular Key Lab of Zhejiang Province, #88 Jiefang Road, Hangzhou, Zhejiang, 310009,China
Keywords: Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.
Abstract: Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.
Export Options
About this article
Cite this article as:
Wang Yi-dong , Liu Zhen-jie , Ren Jun and Xiang Mei-Xiang *, Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update, Current Vascular Pharmacology 2018; 16 (2) . https://dx.doi.org/10.2174/1570161115666170413145705
DOI https://dx.doi.org/10.2174/1570161115666170413145705 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
Vascular Disease Prevention (Discontinued) Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets A Blood Vessel Deformation Model Based Virtual-reality Simulator for the Robotic Catheter Operating System
Neuroscience and Biomedical Engineering (Discontinued) Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease
Current Gene Therapy Pharmaceutical Interventions to Influence Arteriogenesis: New Concepts to Treat Ischemic Heart Disease
Current Medicinal Chemistry Doxycycline Inhibition of Abdominal Aortic Aneurysm Growth - A Systematic Review of the Literature
Current Vascular Pharmacology Graphical Abstracts:
Current Medical Imaging Sam Domains in Multiple Diseases
Current Medicinal Chemistry Review of Trans-Atlantic Cardiovascular Best Medical Therapy Guidelines – Recommendations for Asymptomatic Carotid Atherosclerosis
Current Vascular Pharmacology Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Multimodality Imaging for Interventional Cardiology
Current Pharmaceutical Design The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Recent Advances in Preoperative Cardiac Evaluation
Current Pharmaceutical Design Association of Large Vessel Aneurysm/Pseudo-Aneurysm/Aortitis and Deep Vein Thrombosis in Patients with Behçet’s Disease: A Case Report
Current Rheumatology Reviews